콘텐츠로 이동

절대 금지 약물

The following classifications and sources of medications must absolutely never be used for transgender HRT. Their risks violently outweigh any theoretical benefits. Even if you are completely cut off from legitimate medical pathways, resorting to these alternatives can inflict permanent, fatal damage.

Banned MedicationCore DangerThreat Level
Ethinylestradiol (EE) VTE risk is 6-20x higher than pure E2. Absolutely Banned
Conjugated Equine Estrogens (Premarin) Devastating cardiovascular & clot risks. Absolutely Banned
Medroxyprogesterone Acetate (MPA) Increases breast cancer & cardiovascular events. Absolutely Banned
Veterinary Hormones Uncontrollable doses, unknown excipients, unsterilized. Absolutely Banned
Homebrew / DIY Injectables Severe sepsis risk from unsterile kitchen mixing. Absolutely Banned

Medications like Diane-35 contain 35 μg of EE alongside 2 mg of Cyproterone (CPA). Desperate DIY users frequently take Diane-35 under the delusion that it is a cheap, all-in-one HRT pill. It is not.

  • The CPA in the drug is already pro-coagulant. Stacking it with the lethally pro-coagulant EE amplifies the death risk exponentially.
  • The feminization power of Diane-35 is incredibly weak compared to standard bioidentical estrogen.

Switch to oral bioidentical estradiol (Progynova / Estrace) immediately and source your anti-androgens (CPA, Spiro, Bica) separately. Do not cold turkey your blockers without having a replacement plan.



Medroxyprogesterone Acetate (MPA / Provera)

섹션 제목: “Medroxyprogesterone Acetate (MPA / Provera)”

Demand a prescription for Bioidentical Micronized Progesterone (Prometrium / Utrogestan). You will lose nothing regarding feminization and will drastically lower your cancer and VTE risks.



If your governmental reality completely cuts you off from legal HRT, do not resort to kitchen-sink injectables. Stick to factory-sealed, commercially manufactured oral pills (like Progynova/Estrace/Estrofem) acquired via the gray market. Oral pills are significantly harder to contaminate and infinitely easier to verify for authenticity compared to random vats of oil.


References

  1. Canonico M et al. Hormone therapy and venous thromboembolism: an updated overview. Climacteric 2018.
  2. Vinogradova Y et al. Use of hormone replacement therapy and risk of venous thromboembolism. BMJ 2019.
  3. de Blok CJM et al. Amsterdam cohort 50-year follow-up. Lancet Diabetes Endocrinol 2021.
  4. Hembree WC et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons. J Clin Endocrinol Metab 2017;102(11):3869-3903. DOI:10.1210/jc.2017-01658
  5. Coleman E et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health 2022;23(S1):S1-S259. DOI:10.1080/26895269.2022.2100644
  6. Misakian AL et al. Injectable Estradiol Monotherapy in Transgender Individuals. Endocrine Practice 2025.